How much funding has CanFite raised?

CanFite has raised $15.0M in total funding, most recently a Corporate Round.

Who are CanFite's investors?

CanFite's investors include Giza Venture Capital.

What industry is CanFite in?

CanFite operates in Biotech, Healthcare.

CanFite

Q: Where is CanFite headquartered?

CanFite is headquartered in Petah Tikva, Israel.

IPO

Innovative drug development targeting the A3 adenosine receptor

Petah Tikva, Israel · Founded 1994 · $15.0M raised

Biotech

Healthcare

Headquarters: Petah Tikva
Employees: 11–50
Founded: 1994
Business Model: B2B

Website: canfite.com
Total Funding: $15.0M
Last Round: $15.0M Corporate RoundJul 2025
Rounds: 1

About

Can-Fite BioPharma is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities. The company has an advanced pipeline of proprietary drug candidates in Phase II and Phase III clinical development addressing oncology, inflammatory, and metabolic diseases. Can-Fite's platform technology utilizes the Gi protein-associated A3 adenosine receptor (A3AR) as a therapeutic target — highly expressed in inflammatory and cancer cells while showing low expression in normal cells, making it a unique pharmacological target. Founded in 1994 by Pnina Fishman and Ilan Cohn, Can-Fite is headquartered in Petah Tikva, Israel and is listed on both the Tel Aviv Stock Exchange (TASE:CFBI) and NYSE American (CANF).

Summary

CanFite is a Biotech company based in Petah Tikva, Israel, founded in 1994. It has raised $15.0M in total across 1 round, most recently a $15.0M Corporate Round round in Jul 2025. Investors include Giza Venture Capital.